Latest news with #Visionaire
News18
5 days ago
- Business
- News18
'Your Computer Is At Risk': How Fake Call Centres In Chandigarh Tricity Duped Foreigners
Last Updated: The ED claimed to have busted a major tech fraud racket, following midnight raids on illegal call centres that were duping foreign nationals via spoofing and brand impersonation Pop-up messages, cloned websites, and fake support hotlines, with text as cliche as 'your computer is at risk" – this is how illegal call centres in Chandigarh Tricity played on their victims' fears, most of whom were elderly or non-tech savvy foreign clients. The Enforcement Directorate (ED) claimed to have busted a major tech fraud racket, following midnight searches on illegal call centres in the Chandigarh Tricity area under the provisions of the Prevention of Money Laundering Act (PMLA). It said these entities duped foreign nationals with spoofing and brand impersonation as a core strategy. According to top ED sources, these entities systematically impersonated global tech brands to cheat foreign customers, funnelling proceeds through structured shell companies, spoof websites, payment gateways, and later laundering them via banking channels and hawala. The operations were professionally disguised and run under the garb of BPO and IT services, the sources told News18. The ED sources said entities like Visionaire and Terrasparq have been operational since 2016, showing the longevity and adaptive nature of these networks. WHAT DOES THIS MEAN? The sources said Faisal Rashid Peerzada, director of FSAL Technologies Pvt Ltd, was involved in spoofing, fund control, backend operations. Arshdeep, director of Bios Webtech (US entity) and a close aide of Faisal, helped mask Indian control. They said Sahu Jain, director of Visionaire and Terrasparq, had been operational since 2016 and was linked to US firm CTS Mobility owned by his sister Priya, who was a potential overseas conduit. This is not an isolated scam but a tech-enabled, well-orchestrated fraud ecosystem. They were using front companies in India, showing a calculated effort to evade domestic scrutiny. It also suggested centralised orchestration by Faisal and Jain, they added. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Wire
17-06-2025
- Business
- Business Wire
BioIVT Launches Vision ai re™ to Enhance Drug Development Workflows and Drive Actionable Insights for Precision Medicine
WESTBURY, N.Y.--(BUSINESS WIRE)-- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today introduced Vision ai re™ to support researchers in addressing data reproducibility, scalability, and accessibility challenges that arise when applying artificial intelligence (AI) in target discovery, drug development, and digital pathology. With over 40 years of experience in biospecimen procurement to bring the best products to researchers in need, Vision ai re is BioIVT's latest innovation to transform data into actionable insights, further fueling life-saving medical discoveries. Driving Innovation Through Comprehensive Biospecimen Insights Vision ai re will offer a centralized cloud-based platform that gives clients streamlined access to BioIVT's comprehensive multi-modal data, including clinical, imaging, and multiomics datasets, all supported by advanced AI and bioinformatics tools. As the industry is driven by the promise of AI applications, Vision ai re helps researchers uncover critical patterns and relationships in disease etiology and pathology and enables faster discovery in support of innovative AI models. BioIVT's unique analysis-ready datasets enhance the integration of AI into drug development workflows through pairing with physical biospecimens. The combination of data and samples future-proofs new data generation required to refine AI models used for in silico experiments, resulting in a powerful virtuous cycle. Regulatory bodies continue to recognize the importance of real-world data in evidence-driven decision making. Vision ai re captures comprehensive, real-world data for every patient in one platform, creating cohorts that inform insights to address research demands, with curated data aligned to clinical standards. Specifically, data from decades of ethical biospecimens collections are available, representing all major tumor groups and disease indications, including neurology, autoimmune, and cardiometabolic. The insights represent expansive data from diverse geographies, including clinical data, independent board-certified pathology review of data and scoring, and clinical data alignment. This data integration enables trial groups to drive innovation and accelerate the development of life-changing therapies. 'With our primary focus on empowering customers to develop new, life-saving therapeutics more efficiently, effectively, and safely, we are excited to introduce Vision ai re to the market,' said Dr. Courtney Noah, VP of Scientific Affairs at BioIVT. 'Vision ai re unlocks the full value of biospecimen-derived pathology and multiomics data by providing curated, analysis-ready datasets across multiple disease cohorts. With this innovative platform, researchers can explore complex biological networks and uncover deeper scientific insights, accelerating drug development and enabling the next generation of advanced diagnostics.' If you're interested in learning more, including understanding how Vision ai re can support your workflows, please visit About BioIVT BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME products and research services, cell and gene therapy products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®. For more information, please visit or follow us on LinkedIn.
